Speaker
Description
Abstract
To date, wound healing remains a challenging clinical process due to its multifaceted process occurring in four phases: hemostasis, inflammation, proliferation, and remodeling. Persistence of any of these stages leads to delayed or untimely healing of wounds or relapse, commonly known as chronic wounds. There are several concurrent diseases that prevent the normal processing of healing phases. Diabetes is one such disease condition that could lead to the development of diabetic foot ulcer (DFU), a common long-term complication that impacts amputation of lower limbs to morbidity and mortality of the patients. Increasing research on nature, the richest source of constituents for the treatment of different ailments, suggests the exploration of herbal components in the control of complicated diseases. In this context, naringenin(4,5,7-trihydroxyflavanone), a herbal flavonoid claims to possess antioxidant, antibacterial, anti-inflammatory, and an extensive range of pharmacological and biological activities. Concurrently, literature suggests that vesicular drug delivery systems, specially transferosomes, possess the potential to apply topically to treat DFU boosting maximum penetration into the layers of skin and promoting effective wound healing. In this context, naringenin-loaded transferosomes were developed by a thin film hydration method followed by its characterization for size, zeta potential, EE%, invitro drug release, and morphology. The developed formulation was found to have a vesicular size of 109.1 ± 67.82nm with a zeta potential of –7.56 ± 3.6mV. This size of the vehicle is favorable to apply topically where the negative surface charge will facilitate binding with the cell surface. Other studies on this research are underway. This work will help the scientific community to explore further to tackle DFU.